Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy

Eva Havrdova*, Douglas L. Arnold, Jeffrey A. Cohen, Hans-Peter Hartung, Edward J. Fox, Gavin Giovannoni, Sven Schippling, Krzysztof W. Selmaj, Anthony Traboulsee, D. Alastair S. Compston, David H. Margolin, Karthinathan Thangavelu, Claudio E. Rodriguez, Darlene Jody, Richard J. Hogan, Panos Xenopoulos, Michael A. Panzara, CARE-MS I CAMMS03409 Investigators, Raymond Hupperts, Alasdair J. Coles

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1107-1116
Number of pages10
JournalNeurology
Volume89
Issue number11
DOIs
Publication statusPublished - 12 Sep 2017

Keywords

  • MULTIPLE-SCLEROSIS PATIENTS
  • CONTROLLED PHASE-3 TRIAL
  • LONG-TERM DISABILITY
  • BRAIN ATROPHY
  • INTERFERON-BETA

Cite this

Havrdova, E., Arnold, D. L., Cohen, J. A., Hartung, H-P., Fox, E. J., Giovannoni, G., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., Margolin, D. H., Thangavelu, K., Rodriguez, C. E., Jody, D., Hogan, R. J., Xenopoulos, P., Panzara, M. A., CARE-MS I CAMMS03409 Investigators, Hupperts, R., & Coles, A. J. (2017). Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. Neurology, 89(11), 1107-1116. https://doi.org/10.1212/WNL.0000000000004313